Parkman Healthcare Partners LLC Has $2.25 Million Stock Holdings in InspireMD, Inc. (NYSE:NSPR)

Parkman Healthcare Partners LLC raised its position in InspireMD, Inc. (NYSE:NSPR) by 721.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 854,716 shares of the company’s stock after purchasing an additional 750,635 shares during the period. Parkman Healthcare Partners LLC’s holdings in InspireMD were worth $2,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NSPR. Affiance Financial LLC grew its holdings in InspireMD by 2.9% in the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after buying an additional 5,376 shares in the last quarter. Legato Capital Management LLC acquired a new stake in shares of InspireMD during the 4th quarter worth $47,000. Essex Investment Management Co. LLC acquired a new stake in shares of InspireMD during the 4th quarter worth $191,000. Renaissance Technologies LLC acquired a new stake in shares of InspireMD during the 4th quarter worth $27,000. Finally, Northern Trust Corp grew its holdings in shares of InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after purchasing an additional 24,452 shares in the last quarter. 44.78% of the stock is owned by institutional investors and hedge funds.

InspireMD Stock Down 5.8%

Shares of NSPR stock opened at $2.43 on Wednesday. InspireMD, Inc. has a twelve month low of $2.07 and a twelve month high of $3.80. The company has a market cap of $74.44 million, a P/E ratio of -3.24 and a beta of 0.62. The business has a fifty day simple moving average of $2.64 and a 200 day simple moving average of $2.74.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NSPR. Piper Sandler dropped their price objective on InspireMD from $4.50 to $4.00 and set an “overweight” rating for the company in a research report on Monday. StockNews.com began coverage on InspireMD in a research report on Monday, May 5th. They set a “sell” rating for the company.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.